Dr. Carl H. June is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine and the director of Translational Research at the Abramson Cancer Center at the University of Pennsylvania.
Dr. June is renowned for his groundbreaking work in the development of the successful chimeric antigen receptor (CAR) T cell therapy, which uses genetically modified anti-cancer T cells to eliminate cancer cells. In addition to being named to the TIME 100: Most Influential People of 2018, he has received the 2012 William B. Coley Award for Distinguished Research in Tumor Immunology, the 2015 AACR-CRI Lloyd J. Old Award in Cancer Immunology, and the 2018 Albany Medical Center Prize in Medicine and Biomedical Research. He was elected to the U.S. National Academy of Sciences in 2020. June has also earned membership in the American Association of Physicians, and he continues to investigate and optimize CAR T cell therapy, to make it more effective not only for blood cancers, but also to help patients with other types of cancer.
In addition to being a member of CRI’s Scientific Advisory Council, Dr. June is a member of CRI’s Clinical Leadership Committee.
Read an interview with Dr. Carl June
We’ve come to the tipping point now where there is acceptance that immunotherapy can provide a long-lasting effect and has a lot of promise. There’s always been that promise, but now it’s going to be realized.
Let's spread the word about Immunotherapy! Click to share this page with your community.